06990 SKB BIO-B
- 177.900
- -1.800-1.00%
SKB BIO-B News
Sichuan Kelun-biotech Biopharmaceutical Cancer Drug Gets Regulatory Nod; Shares Up 4%
Sichuan Kelun-biotech Biopharmaceutical (HKG:6990) said the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) approved the investigational new drug applicatio
HKEx News | Kelun-Biotech (06990) rose more than 4%: ADC innovative drug SKB518 for advanced solid tumors approved for clinical trials.
Kolon Life Science-B (06990) rose more than 4%. As of the time of publication, it increased by 4.41% to HKD 179.8, with a turnover of HKD 19.1182 million.
Kolon Life Science-B (06990.HK): The clinical trial application for the injection SKB518 of innovative drug has been approved by the National Medical Products Administration.
On June 17, Golonghui announced that Kelenbotai Biology-B (06990.HK) has received a clinical trial notice for innovative drug SKB518 injection, which the company developed and submitted for clinical trial application approval from the National Medical Products Administration (NMPA) drug evaluation center. SKB518 injection is an innovative antibody conjugated drug developed using the "OptiDCTM" platform technology based on target biological characteristics and has independent intellectual property rights, demonstrating good effectiveness and safety window in preclinical trials and intended for treatment of late-stage solid tumors. The company will proceed in accordance with the
Express News | Sichuan Kelun-Biotech Biopharmaceutical - Investigational New Drug Approval for Innovative Drug- Skb518 for Injection by Nmpa
HKEX Changes | Kelunbotai Biopharmaceutical-B (06990) up nearly 4%, further confirming the potential of SKB264 with ASCO data release.
Zhī tōng cái jīng APP learned that Kelonbotai Biology-B (06990) rose by nearly 4%, and as of the time of publication, it had increased by 3.98% to HKD 169.70, with a turnover of HKD 8.0459 million. CMB International released a research report stating that at the American Society of Clinical Oncology (ASCO) annual meeting, Kelonbotai Biology-B's core product, SKB264, in their opinion, can achieve good efficiency, and the product is expected to be widely used in non-small-cell lung cancer (NSCLC). In addition, the strong results of SKB264's phase III clinical trial for triple-negative breast cancer will help it obtain approval in the mainland.
CMB International: Maintains a "buy" rating on Collinpot Biopharmaceuticals-B (06990) with a target price raised to HKD 246.13.
CMB International expects to incur losses of 659 million yuan, 786 million yuan and 726 million yuan from 2024 to 2026.
Columbotai Bio-B (06990.HK) nominated Lai Degui as a candidate for non-executive director
Gelonghui, May 31 | Columbotai Bio-B (06990.HK) announced that Dr. Wang Jingyi has resigned as the company's executive director with effect from May 31, 2024. The Board of Directors hereby announces that Mr. Lai Degui and Mr. Wan Peng have both resigned as supervisors of the Supervisory Board with effect from May 31, 2024. Following the resignation of Mr. Lai Degui mentioned above, Ms. Liao Yihong was elected Chairman of the Supervisory Board at the Supervisory Board meeting held on May 31, 2024. The board of directors has decided to nominate Mr. Lai Degui as a non-executive director candidate. It is proposed to appoint Mr. Lai Degui as a non-executive director and shareholder for the current year
Columbotai Bio-B (06990): Liao Yihong was elected Chairman of the Supervisory Board
According to Zhitong Finance App, Colunbotai Bio-B (06990) issued an announcement, effective May 31, 2024: Dr. Wang Jingyi has resigned as the company's executive director. Mr. Lai Degui and Mr. Wan Peng have both resigned as supervisors of the Supervisory Board. Ms. Liu Yihong was elected Chairman of the Supervisory Board at the Supervisory Board meeting held on May 31, 2024. Furthermore, the Board of Directors has decided to nominate Mr. Lai Degui as a non-executive director candidate. The proposal to appoint Mr. Lai Degui as a non-executive director is subject to shareholders' approval by means of an ordinary resolution at the recent Annual General Meeting of Shareholders.
Express News | Sichuan Kelun-Biotech Biopharmaceutical - Wang Jingyi Resigned as an Executive Director
Changes in Hong Kong stocks | Collumbotai Bio-B (06990) is now up more than 5%. The company announced SKB264 clinical data and R&D capabilities in the ADC field will be recognized
Collumbotai Bio-B (06990) is now up more than 5%. As of press release, it has risen 4.54% to HK$165.7, with a turnover of HK$27.472,300.
[Broker Focus] CITIC Construction Investment maintains Colun Botai Biotech (06990) “buy” rating, and it is expected that its R&D capabilities in the ADC field will be further recognized
Jinwu Financial News | According to the CITIC Construction Investment Research Report, Colunbotai Biotech (06990) published two clinical data on the core product SKB264 on ASCO. Among them, when used in combination with A167, it showed excellent efficacy in first-line treatment of advanced undriven gene mutation NSCLC, and was also safe; the single drug was also used as a phase III clinical result for TNBC terminal treatment. It is expected that this indication will be approved in the second half of the year. Partner MSD is actively deploying SKB264 global clinical trials. Currently, it has deployed 9 phase III clinical trials, covering various types of lung cancer, breast cancer, and endometrial cancer. Company purpose
Hong Kong Stock Concept Tracking | ADC Pharmaceuticals Enters Acceleration Period, Institutions Are Optimistic About the Innovative Drug Industry's Technology-Driven Cycle (with concept stocks)
ADC drugs have entered a period of acceleration, multiple preclinical studies have been released, and the degree of innovation has increased.
[Broker Focus] CMB International: China's pharmaceutical industry is expected to return to healthy growth and continues to be optimistic about leading innovative drugs and devices and high-growth medical consumer stocks
Jinwu Financial News | CMB International said that since the beginning of the year, the MSCI China Healthcare Index has declined by 21.4%, significantly outperforming the MSCI China Index by 32.5%. The MSCI China Healthcare Index has only rebounded 9% since its low on April 19; currently, the dynamic price-earnings ratio of the industry index is 26.3 times, which is still below the 12-year historical average. It is expected that the medical equipment trade-in policy will soon be implemented. The policy is strong, wide-ranging, and has a long duration, which will effectively stimulate demand for medical devices. The bank looks forward to the introduction of a national policy to support innovative drugs and innovative devices. The bank expects that as industry-supporting policies fall one after another
Sichuan Kelun-biotech Biopharmaceutical to Present Its Cancer Drug Phase 3 Study Results at ASCO
Sichuan Kelun-biotech Biopharmaceutical (HKG:6990) will present results from its Phase 3 study of sacituzumab tirumotecan (sac-TMT) for the treatment of locally recurrent or metastatic triple-negative
Collumbotai Bio-B (06990.HK): Research results announced by the core product Lucan Satuzumab (sAC-TMT) at the 2024 American Society of Clinical Oncology Annual Meeting
Glonghui, May 24 | Columbotai Bio-B (06990.HK) announced that the company will announce its anti-TROP2 ADC lucan satuzumab (sAC-TMT) (formerly SKB264/MK-) at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting to be held in Chicago, USA from May 31 to June 4, 2024 at the Clinical Science Symposium (Abstract #104；下一代抗体药物偶联物：变革在继续) held from 9:45 to 11:15 a.m. local time on June 2, 2024 2870) For previous connections
Columbotai Bio-B (06990) issued 3.648,600 shares on May 16
Colombotai Bio-B (06990) issued an announcement to issue 36 in accordance with the placement agreement on May 16, 2024...
Columbotai Bio-B (06990) completed the placement of a total of 3.648,600 shares to raise approximately HK$541 million
Colombotai Bio-B (06990) issued an announcement. All conditions for the placement have been met, and the placement has already been...
Changes in Hong Kong stocks | Collumbotai Bio-B (06990) rose more than 8%, a record high, and the company plans to raise 1.2 billion dollars. Previously, the main products were approved by the FDA for Phase II testing
Colombotai Bio-B (06990) rose more than 8% to an intraday high of HK$192.8, a record high. As of press release, it rose 7.04% to HK$190, with a turnover of HK$778.87 million.
Changes in Hong Kong stocks | Collumbotai Bio-B (06990) rose more than 7%, and the company plans to refinance 1.2 billion more controlling shareholders to subscribe for nearly 700 million
Collumbotai Biotech (06990) rose more than 7% in early trading. As of press release, it had risen 6.61% to HK$175.9, with a turnover of HK$237.47,800.
Changes in Hong Kong stocks | Columbotai Biotech (06990) has now fallen by more than 4%, net allotment of shares raised more than HK$1.2 billion, of which nearly 700 million were subscribed by controlling shareholders
Columbotai Bio-B (06990) is now down more than 4%. As of press release, it is down 3.35% to HK$155.6, with a turnover of HK$108 million.
Analysis
Price Target
No Data
